Press Release
Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

Cambridge, UK, 11 February 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED). In an exceptional career in Pharmaceutical R&D Professor Chopra has held a number of distinguished roles including Corporate […]

11 February 2019
Read more
Artios Pharma Wins 2018 Lifestars EU Private Finance Raise of the Year Award

Cambridge, UK, 14 November 2018. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, is pleased to announce that it has won the 2018 Lifestars “>£30m EU Private Finance Raise of the Year” Award.

14 November 2018
Read more
Artios Pharma Announces $84 million (£65 million) Series B Financing

Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investors.

10 August 2018
Read more
Artios exercises option to in-license potential first-in-class nuclease development programme

Cambridge, UK, 5 March 2018. Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in […]

5 March 2018
Read more
Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

  Industry leader who brings over 35 years of experience in developing successful pharmaceutical companies Cambridge UK, 26 February 2018 – Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Pierre Legault MBA, CA, CPA as Chairman of its Board of Directors, with immediate […]

26 February 2018
Read more
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

15 September 2017
Read more
Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Cambridge, UK, 4 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Dr Graeme Smith as its Chief Scientific Officer (CSO). 

4 September 2017
Read more
Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

Cambridge, UK, 12 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA nucleases involved in the DDR.

12 June 2017
Read more
Artios announces formation of world-leading Scientific Advisory Board

Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr […]

8 June 2017
Read more
Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Artios Pharma Ltd (“Artios” or “the Company”) Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy  Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team […]

2 November 2016
Read more